Q2FY23 Financial Summary and Strategic Highlights
Neuroscience Portfolio growth drivers
Over the next 12 - 18 months
Pain stim
Above-market growth expected on continued adoption of Intellis™
with DTMTM SCS therapy and recent launch of Vanta TM recharge-
free system; FDA approval of Intellis TM and Vanta™ for the
treatment of diabetic peripheral neuropathy (DPN)
Wwdontic
Vanta™
Recharge
Free SCS
DTMTM SCS on
the Intellis TM
platform
Pelvic Health
Market leader and launching new technology into fast-growing
sacral neuromodulation market; U.S. FDA approval of InterStim TM X
recharge-free device granted
InterStim TM X
primary cell device
Medtronic
Cranial & Spinal Technologies
Continued growth expected of this ~$4.5B business on the rollout of
new spine hardware in the AibleTM Spinal Surgical Suite, adoption of
market leading O-arm TM imaging, Stealth Station TM navigation, and
Mazor™ robotics enabling technology, and surgeon adoption of the
UNiD software platform and the Medicrea implant portfolio.
Catalyft TM
Expandable
Interbody System
Aible™
Spinal Surgical Suite
Neurovascular & ENT
Continued global growth at- or above-market in these two high-
growth markets; just added Intersect ENT sinus implants
Pipeline TM Shield
Embolization Device
with Shield Technology™
Deep brain stimulation
PROPELⓇ and SINUVAⓇ
sinus implants
Continued above-market growth expected on continued adoption
of recently launched sensing products
MP
Percept™ PC
DBS
SenSightTM
Directional Leads
Clinical catalysts
Submitted Inceptiv™M SCS using closed-loop (ECAPS) technology to U.S. FDA
ADAPT-PD U.S. pivotal trial for closed-loop DBS remains on track with enrollment nearing completion
15
Investor Meetings | November 2022
MedtronicView entire presentation